Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

BMY really don't seem to have a clue...

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
longfellow95 Member Profile
 
Followed By 41
Posts 5,779
Boards Moderated 0
Alias Born 04/05/15
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/16/2020 6:59:18 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 10/13/2020 9:31:10 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 9/15/2020 5:14:31 PM
SA Breaking News: ALYI - Alternet Systems revenue surging with new potential customers InvestorsHub NewsWire - 9/14/2020 10:10:04 AM
Traders News Source Identifies Tomorrows NASDAQ's InvestorsHub NewsWire - 9/3/2020 8:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/1/2020 3:24:29 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/20/2020 4:52:41 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 4:44:16 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/7/2020 5:27:35 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/26/2020 5:07:03 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 6/24/2020 6:02:25 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/8/2020 5:02:02 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/4/2020 5:12:40 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/29/2020 5:28:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/27/2020 5:15:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/20/2020 5:06:06 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 5/12/2020 4:12:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2020 5:10:20 PM
Cannabis? CBD? That's Old News, A New Sector Bull Run Has Begun InvestorsHub NewsWire - 4/16/2020 8:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 4/9/2020 5:28:45 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/1/2020 4:41:56 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 3/27/2020 2:47:39 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/16/2020 5:01:48 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 2/24/2020 5:07:15 PM
PURA ALERT - MACD Cross Pushing $0.039 50 Day MA With $0.35 Analyst TGT Recommendation InvestorsHub NewsWire - 2/10/2020 12:50:46 PM
longfellow95   Tuesday, 02/05/19 03:23:15 PM
Re: None
Post # of 323896 
BMY really don't seem to have a clue...

They're running a new randomized open-label P2 in recurrent GBM.

Two arms.

Arm 1. Nivo plus standard dose Bev.

Arm 2. Nivo plus reduced dose Bev

Primary outcome: OS12.

Secondary outcome: OS. Measured up to 3yrs.

https://clinicaltrials.gov/ct2/show/study/NCT03452579#contacts



What do they hope to learn?

I expect the only things they will learn are that Bev caps survival from recurrence at 10 months max with considerable toxicity, and Nivo reduces PFS compared to giving nothing, but adds toxicity.

As was previously demonstrated in Checkmate 143, a P3 no less, when Nivo reduced PFS to 1.5 months...

https://academic.oup.com/neuro-oncology/article/19/suppl_3/iii21/3743874



Pity the patients.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences